Britain backs GSK's gene therapy for 'bubble boy' syndrome
(Reuters) - GlaxoSmithKline's gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($700,000).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Gene Therapy | Genetics | Health | National Institute for Health and Clinical Excelle | UK Health